Policy Number: 204

SOP Title: Levels of IRB Review and Criteria for IRB Approval of Research

Distribution: Scientific Directors; Clinical Directors; Clinical Investigators, IRB Chairs, IRB Administrators, Protocol Navigators

Revision Approval: Michael M. Gottesman -S

Deputy Director for Intramural Research

Implementation date: 10-12-2020
POLICY

A. PURPOSE

1. Describes the levels of ethical review and criteria for approval of human subjects research by the National Institutes of Health (NIH) Institutional Review Board (IRB) (i.e., review by the convened IRB, expedited procedures, limited IRB procedures, or exempt procedures).

2. Describes the criteria for approval of non-exempt human subjects research reviewed by the convened IRB or by a designated reviewer using expedited procedures when the NIH IRB is the Reviewing IRB.

3. Describes the criteria for approval by limited IRB review for certain categories of research determined to be exempt under the 2018 Common Rule at 45 CFR 46.104.

4. Describes the criteria used for exemption determinations by designated exempt reviewers evaluating human subjects research proposed by NIH investigators.

5. Describes investigator responsibilities when submitting research to, or interacting with, the NIH IRB.

B. SCOPE

1. This policy applies to:

   a. NIH investigators when the NIH IRB is the reviewing IRB or when the human subjects research may be exempt from IRB review.

   b. Non-NIH investigators when the NIH is the reviewing IRB.

   c. The NIH IRB, including those experienced IRB members designated to conduct expedited review and limited IRB review.

      I. Note that certain Office of IRB Operations (IRBO) staff members are also IRB members. These include:

         i. IRBO staff designated as expedited reviewers, or who conduct limited IRB review.
ii. IRBO staff designated to review research that is possibly exempt under 45 CFR 46.101 (Pre-2018 Common Rule) or 45 CFR 46.104 (2018 Common Rule).

2. For information about NIH requirements when NIH relies on an external Reviewing IRB, see Policy 105 IRB Reliance.

C. POLICY

1. Application of the DHHS Common Rule (45 CFR 46)

   a. Research initially approved by the IRB, or for which IRB review was waived or determined to be exempt prior to January 21, 2019, is subject to the requirements of the pre-2018 Common Rule;

   b. Research initially approved by the IRB, or for which IRB review was waived or determined to be exempt on or after January 21, 2019, is subject to the requirements of the 2018 Common Rule;

   c. Research subject to the pre-2018 Common Rule may only be transitioned to the 2018 Common Rule if it is determined and documented that transition will occur and that it satisfies the 2018 Common Rule requirements (e.g., as related to exempt research).

2. General requirements

   a. All review of exempt and non-exempt human subjects research will be conducted in accordance with federal regulations and policies.

   b. The convened IRB or expedited reviewer, limited IRB reviewer, or exempt reviewer will review the submission materials in order to determine that the regulatory and policy requirements for approval of research are met. (See Policy 205 Requirements for IRB Submissions.)

   c. Non-exempt human subjects research may be approved by the NIH IRB only when all required regulatory and policy criteria are met, (e.g., 45 CFR 46.109 and 46.111 of the pre-2018 Common Rule or the 2018 Common Rule, and, when applicable, 21 CFR 56.111).

   d. The expedited reviewer, the limited IRB reviewer, or the exempt reviewer may refer any protocol for review by the convened IRB.
e. When the NIH IRB is the Reviewing IRB, it will notify the NIH PI in writing of its decision to approve or disapprove the proposed research, or of any modifications required to secure IRB approval of the research. (45 CFR 46.109)

   I. The expedited reviewer, the limited IRB reviewer, or the exempt reviewer will convey to the NIH PI in writing any determination of approval or referral to the convened IRB.

f. When the NIH IRB is the Reviewing IRB, the period of IRB approval for non-exempt human subjects research is as follows:

   I. For new protocols subject to review by the convened IRB, the period of approval begins on the day research is approved by the convened IRB and continues through a specified date according to continuing review (CR) requirements (see C.2.h. below).

   II. For new protocols eligible for review by expedited procedures, the period of approval begins on the day research is approved by the designated expedited reviewer and continues until the date the study is closed or through a specified date according to CR requirements (see C.2.h. below).

   III. When CR is required, a fixed anniversary date for expiration of the IRB approval will be set at the time of initial review. The protocol will have the same expiration date each year, regardless of the date that CR is approved.

   IV. When CR is not required, the approval period will continue until the date the study is closed.

g. For non-exempt human subjects research, PIs will submit protocols for CR at an interval established by the IRB, unless not required by the IRB for research subject to the 2018 Common Rule requirements.

h. For research subject to either the pre-2018, or the 2018 Common Rule requirements, the convened IRB will conduct CR at an interval established by the IRB (not less than once per year). The IRB shall determine which projects require review more often than annually. However, if the protocol is subject to the 2018 Common Rule and meets the requirements thereof, then CR is not required. The IRB will document the frequency of review in all cases where CR is required.
I. When CR is required, the IRB shall determine which projects need verification from sources other than the investigators to ensure that no material changes have occurred since previous IRB review. (45 CFR 46.108)

II. When CR is required, Office for Human Research Protections (OHRP) guidance, Continuing Review Guidance (2010), and NIH policy does not provide for any grace period extending the conduct of research beyond the expiration date of IRB approval. Therefore, CR and re-approval of research, with or without stipulations/conditions, must occur by midnight of the date when IRB approval expires.

III. All research subject to Food and Drug Administration (FDA) regulation will undergo CR at intervals of not less than once per year, regardless of whether the research is subject to the pre-2018 or 2018 Common Rule.

IV. Unless the convened IRB or expedited reviewer determines and documents otherwise, CR is not required in the following circumstances for research subject to the 2018 Common Rule:

   i. Research eligible for expedited review;

      a. Except that research that was determined to be category 8(b) or 9 (of the HHS Secretary list of categories that may be expedited (v.1998)), and therefore eligible for expedited review, will be required to submit a continuing review at intervals not less than once per year, consistent with OHRP Guidance – 2018 Requirements FAQs - IRB Review.

   ii. Research reviewed by limited IRB review;

   iii. Research that has progressed to the point that it involves only one or both of the following:

   iv. Data analysis of identifiable information and/or identifiable biospecimens;

   v. Access to follow-up clinical data from procedures that subjects would undergo as part of clinical care.

V. For protocols in which CR is not required, all other requirements still apply after initial approval, e.g. submitting amendments to previously approved research, submitting reportable events to the IRB, and obtaining other
ancillary reviews, as applicable. (See Policy 205 Requirements for IRB Submissions, Policy 503 Ancillary Reviews and Policy 801 Reporting Research Events.)

VI. If a study has lapsed due to the PI’s failure to obtain timely CR, the IRB may elect not to review other active or new studies submitted by the PI until the CR is resolved.

i. The PI will submit changes to previously approved research (referred to as “amendments”) for review and approval by the IRB, before these changes are implemented, except when necessary to eliminate apparent immediate hazards to a subject. (45 CFR 46.108)

j. For any non-exempt human subjects research suspended by the IRB, the PI will comply with IRB requirements.

k. For non-exempt human subjects research, once all activities involving human subjects have been completed, and analysis of identifiable private information or identifiable biospecimens is complete, consistent with the analyses described in the protocol, the PI will close the research.

   I. Once the research is closed, all research activities will cease.

   II. Once the study is closed, any analyses using the identifiable private information or identifiable biospecimens from the study, will require prospective IRB review and approval.

l. The PI, Sponsor or IC may seek premature closure of the research. In addition, the IRB can suspend or terminate the research.

3. The convened IRB

   a. The convened IRB has the authority to approve or require modification of the protocol in order to secure IRB approval of non-exempt human subjects research. (See Policy 200 IRB Scope and Authority.)

   b. Only the convened IRB may disapprove research.

      I. The IRB will document the rationale for disapproval in the minutes.

      II. When the convened IRB disapproves the research, it will include in the written notification to the PI, a statement providing the reason(s) for its
decision and give the PI an opportunity to respond in person or in writing. (45 CFR 46.109(d))

c. The convened IRB may make determinations regarding research that is otherwise eligible for expedited review and/or limited IRB review.

d. The convened IRB has the authority to suspend or terminate IRB approval of research that is not being conducted in accordance with the IRB's requirements, federal regulation or NIH policy, or that has been associated with unexpected serious harm to subjects. (See Policy 200 IRB Scope and Authority.)

e. The convened IRB will document its determinations in the minutes of the meeting consistent with the requirements at 45 CFR 46.115.

4. Expedited Procedures

a. Expedited procedures may be performed by an IRB Chair or expedited reviewers designated by the Chair, in consultation with the IRBO as needed.

b. The expedited reviewer may use expedited procedures for the following categories of human subjects research:

   I. Research appearing in the Secretary’s List of Categories specified at 45 CFR 46.110(a) and satisfying 45 CFR 46.110(b)(1)(i) of the 2018 Common Rule and 45 CFR 46.110(b)(1) of the pre-2018 Common Rule; or

   II. Minor changes in previously approved research during the period for which approval is authorized (45 CFR 46.110(b)(1)(ii) of the 2018 Common Rule and 45 CFR 46.110(b)(2) of the pre-2018 Common Rule); or

   III. Research subject to the 2018 Common Rule for which limited IRB review is a condition of exemption. (45 CFR 46.110(b)(1)(iii) of the 2018 Common Rule).

   IV. The expedited reviewer will document that the criteria for approval at 45 CFR 46.111 have been met, and which of the criteria in C.4.b.I. – C.4.b.III. above were met when approving research by expedited procedures.

   V. The prepared agenda of the IRB will advise IRB members of research proposals that have been approved by expedited procedures.
5. Exempt Research

a. At the NIH, the IRBO Director or designee has the exclusive authority to determine that human subjects research is exempt under 45 CFR 46. (See 45 CFR 46.104 of the 2018 Common Rule and 45 CFR 46.101(b) of the pre-2018 Common Rule.)

   I. Only designated exempt reviewers may make determinations that human subjects research is exempt under 45 CFR 46.

   II. Investigators do not have the authority to determine that human subjects research is exempt.

b. The exempt reviewer will document the exemption category under which the approval was granted.

6. Exempt Research Requiring Limited IRB Review

a. In order to be exempt, certain human subjects research subject to the 2018 Common Rule may require limited IRB review. Limited IRB review may be conducted by a designated limited IRB reviewer using expedited procedures.

b. Research that may be exempt, for which limited IRB review may be used, includes:

   I. Research that only includes interactions involving educational tests, survey procedures, interview procedures, or observation of public behavior, when the information obtained is recorded by the investigator in such a manner that the identity of the human subjects can readily be ascertained directly or through identifiers linked to the subjects (45 CFR 46.104(d)(2)(iii));

   II. Research involving benign behavioral interventions in conjunction with the collection of information through verbal or written responses or audiovisual recordings, if the subject prospectively agrees to the intervention and information collection, and when the information obtained is recorded by the investigator in such a manner that the identity of the human subjects can readily be ascertained, directly or through identifiers linked to the subjects (45 CFR 46.104(d)(3)(i)(C)); or
III. Certain storage, maintenance or use of identifiable private information or identifiable biospecimens for secondary research for which broad consent is required (45 CFR 46.104(d)(7), and (d)(8)).

IV. The limited IRB reviewer will document the exemption category under which the approval was granted.

V. The prepared agenda of the IRB will advise IRB members of research proposals that have been approved by limited IRB procedures.

7. Review of Research Involving Vulnerable Populations

a. When reviewing research that includes federally defined vulnerable populations (i.e., prisoners, pregnant women, fetuses, neonates, and/or children), the convened IRB, expedited reviewer, limited IRB reviewer, or exempt reviewer, shall make all required determinations as specified under 45 CFR 46 subparts B, C and/or D, as well as 21 CFR 50 subpart D, and will consider whether adequate provisions have been made to protect the safety, rights, and welfare of the subjects and to minimize research risks unique to the population. These determinations shall be consistent with both regulation and NIH policy. (See Policies 402 Research Involving Children, 400 Research Involving Pregnant Women, Human Fetuses and Neonates and 401 Research Involving Prisoners.)

b. Research subject to 45 CFR 46 subpart B, C and/or D may not be eligible for exemption due to restricting regulation or policy. (See Policies 402 Research Involving Children, 400 Research Involving Pregnant Women, Human Fetuses and Neonates and 401 Research Involving Prisoners.)

c. When reviewing research that includes other populations determined by NIH policy as vulnerable, such as decisionally impaired adults or NIH staff participating in research, the convened IRB or expedited reviewer shall assure that additional NIH policy requirements are met consistent with Policy 403 Research Involving Adults Who Lack Decision-making Capacity to Consent to Research Participation and Policy 404 Research Involving NIH Staff as Subjects.

1 Exemptions related to broad consent for the maintenance, storage and secondary use of identifiable private information or identifiable biospecimens at 45 CFR 46.104(d)(7) or (8) are not being implemented in the NIH IRP at this time.
d. Additionally, when some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as economically or educationally disadvantaged persons, additional safeguards may be required by the IRB.

D. DEFINITIONS

Definitions demarcated with (Pre-2018 Common Rule definition) apply to research approved (or deemed to be exempt or for which no IRB review was required under the regulations) prior to the effective date of the 2018 Common Rule (January 21, 2019). Definitions demarcated with (2018 Common Rule definition) apply to all research approved by an IRB (or deemed to be exempt or for which no IRB review was required under the regulations) on or after January 21, 2019 and to research transitioned to the 2018 requirements in accordance with HRPP policy.

1. Amendment – A proposed modification of previously approved exempt research, previously exempt research for which Limited IRB review is required, or previously approved non-exempt human subjects research.

2. Continuing review requirements (Pre-2018 Common Rule) – The ongoing, scheduled IRB review of a previously approved non-exempt human subjects research study, at intervals appropriate to the degree of risk, but not less than once per year.

3. Continuing review requirements (2018 Common Rule) – The ongoing, scheduled IRB review of a previously approved non-exempt human subjects research study, at intervals appropriate to the degree of risk, but not less than once per year, except as described in 45 CFR 46.109(f) for research that is subject to the 2018 Common Rule.

4. Convened IRB – Committee review of human subjects research by an IRB that meets the membership requirements specified in federal regulations and as described in Policy 201 IRB Membership and Composition.

5. Experienced IRB member – An IRB member who has demonstrated, during a period of active participation, a broad understanding and competency in human subjects protection ethics, board operations, and regulatory requirements.

6. Expiration Date – The last date research activities can be performed under the auspices of IRB approval.

7. Human Subject (Pre-2018 Common Rule) – A living individual about whom an investigator (whether professional or student) conducting research obtains:
   (1) Data through intervention or interaction with the individual, or
   (2) Identifiable private information.
8. **Human Subject (2018 Common Rule)** – A living individual about whom an investigator (whether professional or student) conducting research:
   Obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens; or
   Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens.

9. **Initial Review** – The first submission of a research protocol for review of exempt or non-exempt human subjects research.

10. **Limited IRB Review (2018 Common Rule)** – Review by limited IRB procedures to ensure exempt research meets the requirements referenced at 45 CFR 46.104 and 46.111(a)(7) or 46.111(a)(8).

11. **Minimal Risk** – The probability and magnitude of harm or discomfort anticipated in the research are not greater, in and of themselves, than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. 45 CFR 46.102(i) (pre-2018 Common Rule), 45 CFR 46.102(j) (2018 Common Rule) and 21 CFR 50.3(k).

12. **Minimal Risk (for Prisoner Research under Subpart C)** – The probability and magnitude of physical or psychological harm that is normally encountered in the daily lives, or in the routine medical, dental, or psychological examination of healthy persons. (45 CFR 46.303(d)) At NIH, “healthy person” is interpreted to mean healthy persons who are not incarcerated.

13. **Minor Changes** – Changes to the research that do not have the potential to adversely impact the risk/benefit assessment and does not substantially alter the research aims.

14. **Research (Pre-2018 Common Rule)** – A systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge. Activities which meet this definition constitute research for purposes of this policy, whether or not they are conducted or supported under a program which is considered research for other purposes. For example, some demonstration and service programs may include research activities.

15. **Research (2018 Common Rule)** – A systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge. Activities that meet this definition constitute research for purposes of this policy, whether or not they are conducted or supported under a program that is considered research for other purposes. For example, some demonstration and service
programs may include research activities. For purposes of this part, the following activities are deemed not to be research.

a) Scholarly and journalistic activities (e.g., oral history, journalism, biography, literary criticism, legal research, and historical scholarship), including the collection and use of information, that focus directly on the specific individuals about whom the information is collected.

b) Public health surveillance activities, including the collection and testing of information or biospecimens, conducted, supported, requested, ordered, required, or authorized by a public health authority. Such activities are limited to those necessary to allow a public health authority to identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health importance (including trends, signals, risk factors, patterns in diseases, or increases in injuries from using consumer products). Such activities include those associated with providing timely situational awareness and priority setting during the course of an event or crisis that threatens public health (including natural or man-made disasters).

c) Collection and analysis of information, biospecimens, or records by or for a criminal justice agency for activities authorized by law or court order solely for criminal justice or criminal investigative purposes.

d) Authorized operational activities (as determined by each agency) in support of intelligence, homeland security, defense, or other national security missions.

16. **Reviewing IRB** – The IRB responsible for reviewing human subjects research and determining that the research meets the required criteria for approval under the HHS regulatory requirements at 45 CFR 46 and, as applicable, the pertinent Subparts of 21 CFR.

17. **Study Closure** – Closure of a non-exempt human subjects research protocol for which all human subjects activities are complete, and for which access to identifiable private information or identifiable biospecimens consistent with the purposes described in the IRB-approved protocol has ceased. This includes premature closure with IRB approval that takes into consideration the rights, safety and welfare of any enrolled subjects.

E. RESPONSIBILITIES AND REQUIREMENTS

1. **Principal Investigator Responsibilities and Requirements**

   a. NIH Principal Investigators (PIs) are responsible for being knowledgeable as to whether their research activities meet the definition of human subjects research (see
Definitions above) and whether the research is eligible for an exempt determination (see C.5. above and E.4. below) or requires IRB review.

b. NIH PIs are responsible for submitting all exempt and non-exempt human subjects research for review as specified in Policy 205 Requirements for IRB Submissions.

c. NIH PIs are responsible for assuring all submissions are entered into the NIH electronic IRB system for routing to the NIH IRB, whether evaluated by the convened IRB, expedited reviewer, exempt reviewer, or by the limited IRB. (See Policy 205 Requirements for IRB Submissions.)

d. For multi-site research when the NIH IRB is the Reviewing IRB, the NIH PI is responsible for communicating IRB determinations and approvals to the PI/Lead Site Investigator of the ceding institution consistent with Policy 105 IRB Reliance.

e. When the NIH is relying on an external Reviewing IRB, the NIH PI must first submit the protocol for review and confirmation of compliance with institutional requirements in the NIH electronic IRB system, prior to submitting to the external Reviewing IRB. (See Policy 105 IRB Reliance.)

   I. In addition, the PI must also follow the submission requirements of the external Reviewing IRB. (See Policy 105 IRB Reliance.)

f. NIH PIs must ensure that human subjects research is not initiated until notice of IRB approval or exempt determination, as applicable, is received.

g. For non-exempt human subjects research, when CR is required, it is the PI’s responsibility to obtain CR prior to expiration to avoid lapse in IRB approval. The PI must provide the IRB with the information through the NIH electronic IRB system, in sufficient time to allow the IRB to perform the CR, and no later than 6 weeks prior to the expiration date of the study. Failure to allow sufficient time for IRB review may result in a lapse in approval.

   I. If CR and approval has not occurred by the study expiration date, the study will be considered to have a lapse in IRB approval.

      i. All research activities must stop upon lapse of IRB approval (including recruitment enrollment, interventions, interactions and data analysis) – even if no notice of lapse of IRB approval is received.

      ii. However, when it is in the best interests of already enrolled subjects to continue in the research during the period of lapse in IRB approval, the
IRB has the authority to, or the PI may request from the IRB permission to, continue the participation of already enrolled subjects during this period.

iii. When a study has lapsed due to the PI’s failure to obtain timely CR (e.g., submit a CR form, or failure to respond to questions or stipulations regarding the CR), the IRB will not review other or new studies submitted by the PI until the CR is resolved.

iv. If a study has lapsed for longer than 45 days (see C.2.h.VI. above), the PI must submit a new initial review in order to continue the research.

II. For protocols for which the IRB has determined that CR is not required, PIs are required to comply with all other requirements after initial approval, e.g., submitting amendments to previously approved research, submitting reportable events to the IRB, and obtaining other ancillary reviews, as applicable. Once research is complete, the PI must close the protocol (see E.1.j. below). (See Policy 205 Requirements for IRB Submissions, Policy 106 Ancillary Reviews and Policy 801 Reporting Research Events.)

h. NIH PIs must ensure that all changes (amendments) to previously approved research are submitted for IRB review and approval prior to instituting any change, unless that change is required to prevent an immediate risk of harm to subjects, (see C.2.i. above).

I. When the PI has taken an action to eliminate an immediate hazard to a subject, the PI will notify the IRB within 7 days of such a change. Such an action is considered a “major deviation” for the purposes of reporting. (See Policy 801 Reporting Research Events.)

II. For research that has previously been determined to be exempt, PI’s must submit amendments for review and approval prior to instituting any changes.

i. When the research has been suspended, if subjects are enrolled on the research, the PI must provide a plan to the IRB for its consideration that takes into account the continued rights, safety and welfare of enrolled subjects during the period of suspension

I. The NIH investigator must obtain IRB approval before the research may be restarted.
j. For non-exempt human subjects research, the NIH PI will close the research when all subjects have completed research interactions and interventions and primary data analysis is complete. This includes analysis of identifiable private information or identifiable biospecimens, consistent with the analyses described in the protocol (see C.2.k. above).

   i. When studies are closed because all study activities are complete, they may be closed as follows:

   ii. Studies for which CR is required, the PI may submit the study closure form at any time during the approval period, but no later than the expiration date of the study.

   iii. Studies for which CR is not a requirement, the PI must submit the study closure form when all human subjects research activities are complete.

II. When the PI, Sponsor, or the IC prematurely closes the research, the PI must notify the IRB that the study will be closed prematurely.

   i. If research prematurely closes or the IRB terminates its approval and subjects are enrolled, the PI must provide the IRB for its consideration:

      • A plan for orderly closure that takes into account the rights, safety and welfare of enrolled subjects; and

      • The proposed correspondence to subjects regarding premature closure of the study, if not already approved by the IRB as part of an amendment.

III. The PI is responsible for maintaining study records after study closure consistent with Policy 300 Investigator Responsibilities. In most cases, to determine how long to retain study records, the PI should use the closure date provided by the IRB. The closure date is the date of the closure letter to the PI and serves as the starting point for this requirement. The letter confirms that the IRB has reviewed the study completion form.

2. General Requirements for IRB Approval of Research

   a. The IRBO must review all human subjects research submitted via the NIH electronic IRB system to determine the appropriate level of review.
b. When conducting its review, the convened IRB, expedited reviewer, limited IRB reviewer, or exempt reviewer must review the submission materials in order to determine that the regulatory and policy requirements for approval of research are met, or whether more information is needed to make a determination. (See Policy 205 IRB Submissions.)

c. The convened IRB must review research referred to it by the expedited reviewer, limited IRB reviewer, exempt reviewer, or the IRBO Director.

d. The convened IRB or expedited reviewer conducts a general assessment of the project’s research design to assess if the research is of sound design and scientific validity. (45 CFR 46.111(a)(1) of the pre-2018 Common Rule, 45 CFR 46.111(a)(1) of the 2018 Common Rule, and, when applicable, 21 CFR 56.111(a)(1))

I. The primary responsibility for this type of assessment (referred to as “Scientific Review”), however, belongs to the submitting Principal Investigator’s (PI’s) Institute/Center (IC). The IC generally does this by considering the purpose of the research, statistical design and power, data analysis, clinical and data monitoring plan, qualifications of the research personnel, and adequacy of resources to conduct the research consistent with the requirements of the Policy for Scientific Review of Clinical Protocols Utilizing the NIH Intramural Program. (See Policy 106 Ancillary Reviews).

e. For all human subjects research, the convened IRB, expedited reviewer, or the limited IRB reviewer shall determine and document whether the research presents only minimal risk or greater than minimal risk.

f. For non-exempt human subjects research, the convened IRB, or the expedited reviewer, shall determine and document whether there is prospect of benefit, if any, that may result from participation in the research, consistent with 45 CFR 46.111 of both the pre-2018 Common Rule or the 2018 Common Rule, and, when applicable, 21 CFR 56.111.

g. Non-exempt human subjects research may be approved by the NIH IRB only when all required regulatory and policy criteria are met, (e.g., 45 CFR 46.109 and 46.111 of the pre-2018 Common Rule or the 2018 Common Rule, and, when applicable, 21 CFR 56.111).

h. The convened IRB must conduct CR at an interval established by the IRB (but not less than once per year), unless the protocol is subject to the 2018 Common Rule and
meets the requirements of 45 CFR 109(e) and (f), and CR is not required (see C.2.h. above).

i. When CR is required, the IRB must:
   I. Determine which projects require review more often than annually; and
   II. Document the frequency of review; and
   III. Determine which projects need verification from sources other than the investigators that no material changes have occurred since previous IRB review. (45 CFR 46.108).

j. The IRBO will notify the PI when IRB approval is approaching expiration and the research is due for CR in order to avoid a lapse in IRB approval.
   I. Generally, at the time of CR, the convened IRB or expedited reviewer will not re-approve the research more than 30 days prior to study expiration. If the reapproval is greater than 30 days from the date of study expiration, the expiration date for the study will change. The new expiration date will be no more than 12 months from that reapproval.

k. If CR is not required by regulation, but the IRB in its discretion decides to require CR, it will inform the PI of the reasons why CR is required. (45 CFR 46.109(f) of the 2018 Common Rule.)

l. When CR is not required, the IRB will inform the PI, at the time of approval, that:
   I. All other institutional and regulatory requirements continue to apply, (e.g., the requirement to obtain ancillary reviews, to report research events, and to submit amendments.); and
   II. The IRB’s approval will continue until the date the study is closed.

m. When CR is not required, the IRBO will send annual reminders to the PI that all other requirements continue to apply (e.g., E.2.I.I.) and to remind the PI to close the study if research activities are complete.
   I. Every 3 years, a triennial study closure reminder will be sent to the PI by the IRBO requesting affirmation that the study is open. If no reply is received by the IRBO, the study may be closed administratively.
n. When research involves federally defined vulnerable populations, the convened IRB or expedited reviewer shall make and document the required risk/benefit determinations as specified under 45 CFR 46 subparts B, C and/or D, as well as 21 CFR 50 subpart D when applicable. (See Policies 402 Research Involving Children, 400 Research Involving Pregnant Women, Human Fetuses and Neonates and 401 Research Involving Prisoners.)

o. For research involving adults who lack decision-making capacity to consent to research participation, the convened IRB or expedited reviewer shall make, and document, risk and benefit determinations consistent with Policy 403 Research Involving Adults Who Lack Decision-making Capacity to Consent to Research Participation.

p. For research involving NIH staff as subjects, the convened IRB or expedited reviewer shall make, and document that there are adequate safeguards are in place consistent with Policy 404 Research Involving NIH Staff as Subjects.

q. The IRB will set the period of approval for non-exempt human subject research consistent with the requirements outlined in C.2.f. above.

r. The convened IRB, expedited reviewer, or limited IRB reviewer must make and document one of the following determinations:

I. Approve as submitted – Approval of a research study by the convened IRB, or by the expedited reviewer, or by the limited IRB reviewer.

II. Approve with stipulations – Approval of a research study by the convened IRB, or by the expedited reviewer, or limited IRB reviewer contingent on stipulated changes to the research.

s. The IRBO must ensure that IRB members will receive a report of research approved by expedited procedures (see C.4.b. above), including by limited IRB review (see C.6.b.V. above), that occur between convened meetings.

t. Only the convened IRB can take the following actions:

I. Table - An action taken by the convened IRB on a research study requiring resolution of one or more criteria for approval, or other substantive issues have been identified (e.g., risks have not been identified, risks are significant and have not been adequately minimized, or the safety monitoring plan is not adequate). When such an action is taken, the IRB may stipulate substantive
changes to the research study. Tabled actions must be reviewed by the convened IRB in order to be approved.

II. Disapprove - An action taken by the convened IRB on a research study that cannot be approved in its present form or is inappropriate based on its present design (e.g., for reasons such as subject safety or scientific validity).

u. The convened IRB may suspend research activities or terminate IRB approval for previously approved research (including research approved by limited IRB review, expedited procedures, or research previously determined to be exempt). (45 CFR 46.113)

I. When research is suspended or terminated, the IRB must document the rationale for this action, and promptly notify the PI and institutional leadership.

II. In such cases, the PI must work with the IRB to establish a plan to ensure the continued rights, safety and welfare of any subjects actively enrolled on the protocol.

III. These actions will be reported by OHSRP to OHRP and the FDA consistent with the requirements in Policy 801 Reporting Research Events.

3. Review of Research by Expedited Procedures

a. Human subjects research reviewed and approved by expedited procedures must satisfy the applicable regulatory requirements (e.g., 46.109, 46.110, and 46.111 of the pre-2018 Common Rule or the 2018 Common Rule and, when applicable, 21 CFR 56.110 and 56.111).

b. The expedited reviewer may require additional information in order to determine whether the study may be approved or requires referral to the convened IRB.

c. The expedited reviewer is responsible for determining and documenting that the applicable regulatory requirements are satisfied for research in which expedited review is available and when approving research (initial or continuing review) or amendments to previously approved research.

d. When the research is subject to the 2018 Common Rule requirements, if the expedited reviewer determines that the proposed research activities appear on the List of Categories but are more than minimal risk, the reviewer must document a rationale
for this determination, and refer the submission for review by the convened IRB. (45 CFR 46.110(b)(1)(i) of the 2018 Common Rule).

e. Expedited Review procedures will not be used for research involving prisoners. (401 Research Involving Prisoners).

f. Research may only be disapproved by full board procedures. (45 CFR 46.108(b), 46.109(a) and 46.110(b)(2) of the pre-2018 and 2018 versions of the Common Rule).

4. Exempt Research

a. Research reviewed and determined to be exempt by exempt reviewers must satisfy the applicable regulatory requirements (e.g., 45 CFR 46.101(b) of the pre-2018 Common Rule, or 45 CFR 46.104 of the 2018 Common Rule).

b. The exempt reviewer must review the protocol and all materials provided in the submission to determine and document whether the regulatory and policy requirements for exempt research are satisfied, consistent with Policy 205 Requirements for IRB submissions.

c. When evaluating exempt research, the designated exempt reviewer is responsible for determining and documenting that the research satisfies the criteria for exemption as follows:

I. For research initially determined to be exempt on or after January 21, 2019 (including research subject to the pre-2018 Common Rule and later transitioned to an exempt category of the 2018 Common Rule), the determination will be made based upon the 2018 Common Rule criteria specified at 45 CFR 46.104 and, as applicable, 45 CFR 46.110(b) and/or that the criteria for approval at 45 CFR 46.111(a)(7) and/or (a)(8) are met.

II. For research initially approved on or before January 20, 2019, or for which IRB review was waived or determined to be exempt, the pre-2018 Common Rule criteria at 45 CFR 46.101(b) will apply.

d. Exempt reviewers cannot disapprove research activities proposed under the exempt framework. Research may only be disapproved by full board procedures. (45 CFR 46.109(a) of the pre-2018 and 2018 versions of the Common Rule)

e. Research subject to 45 CFR 46 B, C and/or D and policy may not be eligible for exemption. (See Policies 402 Research Involving Children, 400 Research Involving
Pregnant Women, Human Fetuses and Neonates, and 401 Research Involving Prisoners.

5. Exempt Research Requiring Limited IRB Review

a. This research may be approved as exempt when the limited IRB reviewer determines that the criteria specified at 45 CFR 46.104(d) categories 2, 3, 7 and/or 8 and the criteria specified at 45 CFR 46.111(a)(7) and/or (a)(8) are met.

b. The limited IRB reviewer must make and document determinations consistent with C.6.b.IV. above. The limited IRB reviewer will review the protocol and all other submitted materials to determine that the regulatory requirements for exempt research are satisfied consistent with Policy 205 Requirements for IRB Submissions.

c. The limited IRB reviewer may use expedited review procedures.

d. The limited IRB reviewer can approve, or require modifications to secure approval of, research activities proposed under the limited IRB review framework. (45 CFR 46.109(a) of the 2018 Common Rule)

e. The limited IRB reviewer cannot disapprove the research activities proposed under the limited IRB review framework. Research may only be disapproved by full board procedures. (45 CFR 46.108(b) and 46.109(a) of the 2018 Common Rule).

F. REFERENCES

1. Federal Regulations

HHS: 45 CFR 46, Secretary’s List of Categories at 45 CFR 46.110(a):

FDA: 21 CFR parts 50 (https://www.ecfr.gov/cgi-bin/text-idx?SID=093516d4904769f3d9c8e9ee097a2a23&mc=true&tpl=/ecfrbrowse/Title21/21cfr50_main_02.tpl) and 56 (https://www.ecfr.gov/cgi-bin/text-idx?SID=093516d4904769f3d9c8e9ee097a2a23&mc=true&node=pt21.1.56&rgn=div5)

2. NIH Policy

Policy 105 IRB Reliance
Policy 106 Ancillary Reviews
Policy 200 IRB Scope and Authority
Policy 201 IRB Membership and Composition
Policy 205 Requirements for IRB Submissions
Policy 400 Research Involving Pregnant Women, Human Fetuses and Neonates
Policy 401 Research Involving Prisoners
Policy 402 Research Involving Children
Policy 403 Research Involving Adults Who Lack Decision-making Capacity to Consent to Research Participation
Policy 404 Research Involving NIH Staff as Subjects
Policy 801 Reporting Research Events
Policy for Scientific Review of Clinical Protocols Utilizing the NIH Intramural Program

3. Guidance:
   OHRP Guidance – 2018 Requirements FAQs - IRB Review

G. APPENDICES: None

H. REVISION HISTORY: NA

I. SUPERSEDES DATE: 10/12/2020
   SOP 6 – Determinations, Including Exemptions Made by the Office of Human Subjects Research Protections (OHSRP)
   SOP 7 – Requirements for the Ethical and Regulatory Review of Research by NIH Institutional Review Boards (IRBS)